Tirapazamine: A bioreductive anticancer drug that exploits tumour hypoxia

Expert Opinion on Investigational Drugs

Volumn 9, Issue 12, 2000, Pages 2889-2901

  Denny, W A ^a   Wilson, W R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cytochrome P450 reductase; DNA break; Free radical; Hypoxia selective cytotoxin; Tirapazamine

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 NITROIMIDAZOLE; 4 HYDROXYCYCLOPHOSPHAMIDE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; COPOLYMER; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DNA; DOXORUBICIN; ETOPOSIDE; GLUCURONIDE; MITOFLAXONE; NAVELBINE; PACLITAXEL; POLY(CARBOXYPHENOXYPROPYL SEBACATE); PORFIROMYCIN; SEROTONIN; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL HYPOXIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DIARRHEA; DNA CROSS LINKING; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG DNA INTERACTION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOUSE; MUSCLE CRAMP; NAUSEA; NONHUMAN; OTOTOXICITY; OXIDATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SLOW RELEASE FORMULATION; SQUAMOUS CELL CARCINOMA; TARGET CELL DESTRUCTION; VOMITING;

EID: 0033653205     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.12.2889     Document Type: Article

References (112)

1. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays
2. Hypoxic regions exist in human prostate carcinoma
3. Intratumoral p02-measurements as predictive assay in the treatment of carcinoma of the uterine cervix
4. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome
5. Hypoxic cervical cancers with low apoptotic index are highly aggressive
6. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma
7. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
8. Hypoxia specific cytotoxins in cancer therapy
9. Recent developments in the design of bioreductive drugs
10. Bioreductive drugs into the next millennium
11. Preclinical studies of porfiromycin as an adjunct to radiotherapy
12. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
13. Simple synthesis of 3-amino-1,2,4-benzotriazine 1,4-dioxide
14. A convenient synthesis of 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR 4233) and related compounds via nucleophilic aromatic substitution between nitro arenes and guanidine base
15. The one-electron reduction potential of 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) - A hypoxia-selective bioreductive drug
16. Identification of two major reduction products of the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide
17. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233)
18. Microsomal reduction of 3-amino-1,2,4-benzotriazine-1,4-dioxide to a free radical
19. Direct evidence for bimodal DNA damage induced by tirapazamine
20. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: The drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions
21. DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233): Evidence for involvement of the hydroxyl radical
22. Dual action of tirapazamine in the induction of DNA strand breaks
23. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine
24. Tirapazamine (SR 4233) interrupts cell cycle progression and induces apoptosis
25. Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (tirapazamine)
26. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
27. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin
28. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
29. Cells at intermediate oxygen levels can be more important than the 'hypoxic fraction' in determining tumor response to fractionated radiotherapy
30. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant
31. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells
32. Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs
33. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: The cobalt(III)-nitrogen mustard complex SN 24771
34. Tirapazamine: A hypoxia activated small cellisomerase II inhibitor
35. Enzymology of tirapazamine metabolism: A review
36. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin
37. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233)
38. Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H:(Quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumor cells
39. Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations
40. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents
41. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver
42. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)
43. Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small cell lung cancer cell lines?
44. Overexpression of human NADPH-cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069
45. NADPH: Cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
46. SR 4233 (Tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours
47. The hypoxic cell: A target for selective cancer therapy. Eighteenth Bruce F. Cain Memorial Award lecture
48. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes
49. Formation of the tirapazamine toxic free radical intermediate occurs through the nuclear matrix
50. Microdialysis sampling with on-line microbore HPLC for the determination of tirapazamine and its reduced metabolites in rats
51. Dual-electrode amperometric detection for the determination of SR4233 and its metabolites with microbore liquid chromatography
52. Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation
53. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice
54. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans - Retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial
55. Microdialysis sampling in tumor and muscle: Study of the disposition of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (SR 4233)
56. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice
57. Evaluation of bioreductive drugs in multicell spheroids
58. Extravascular diffusion of tirapazamine - Effect of metabolic consumption assessed using the multicellular layer model
59. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model
60. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233
61. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors
62. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation
63. Therapeutic advantage of hypoxic cells in tumors: A theoretical study
64. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen
65. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation
66. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation
67. Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice
68. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma
69. Radiosensitization of a mouse tumor model by sustained intratumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device
70. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin
71. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
72. Potentiation of cisplatin activity by the bioreductive agent tirapazamine
73. Tirapazamine: A new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small cell lung cancer
74. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts
75. The in situ tumour response to combinations of cyclophosphamide and tirapazamine
76. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
77. Combinations of TNP-470 or SR-4233 with antitumor alkylating agents in EMT-6 spheroids and monolayers
78. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours
79. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine
80. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft
81. Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT)
82. Bioreductive drugs and the selective induction of tumour hypoxia
83. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma
84. Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid
85. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents
86. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid
87. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
88. Scintigraphic imaging of the hypoxia marker 99mTechnetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; Prognox): Non-invasive detection of tumor response to the anti-vascular agent 5,6-dimethylxanthenone-4-acetic acid
89. Phase I pharmacokinetic and pharmacodynamic study of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
90. Phase I and pharmacokinetic study of tirapazamine (SR-4233) administered every three weeks
91. Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation
92. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors
93. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas - A Phase II study
94. Single-arm, open-label Phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme
95. Tirapazamine: Laboratory data relevant to clinical activity
96. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer
97. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors
98. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma
99. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma
100. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small cell lung cancer
101. Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer - A Phase II study
102. Tirapazamine-cisplatin - The synergy
103. Tirapazamine plus cisplatin versus cisplatin in advanced non-small cell lung cancer: A report of the international CATAPULT I study group
104. PET evaluation of hypoxia and response in locally advanced head and neck cancer treated on a Phase I trial of radiotherapy, tirapazamine and cisplatin (10th NCI-EORTC Symposium)
105. Extraordinary tumor control in Phase I trial of concurrent tirapazamine cisplatin and radiotherapy for far advanced head and neck cancer
106. Tirapazamine, cisplatin and fluorouracil as induction chemotherapy and simultaneous chemoradiotherapy for organ preservation in advanced head and neck cancer
107. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: Relationship to tumor hypoxia
108. Phase II study of the combination of vinorelbine, cisplatin and tirapazamine in advanced non-small cell lung cancer (NSCLC)
109. Phase I trial of the addition of paclitaxel to tirapazamine (TPZ) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC)
110. Phase I study of tirapazamine and cyclophosphamide in children with refractory solid tumours
111. Phase I study of intravenously administered tirapazamine (WIN 59075) plus cyclophosphamide (9th NCI-EORTC Symposium)
112. Evaluation of ocular safety - Tirapazamine plus cisplatin in patients with metastatic melanomas